BRPI1012301A2 - composições de melfalano injetáveis compreendendo um derivado de ciclodextrina e métodos de preparar e usar o mesmo - Google Patents
composições de melfalano injetáveis compreendendo um derivado de ciclodextrina e métodos de preparar e usar o mesmoInfo
- Publication number
- BRPI1012301A2 BRPI1012301A2 BRPI1012301A BRPI1012301A BRPI1012301A2 BR PI1012301 A2 BRPI1012301 A2 BR PI1012301A2 BR PI1012301 A BRPI1012301 A BR PI1012301A BR PI1012301 A BRPI1012301 A BR PI1012301A BR PI1012301 A2 BRPI1012301 A2 BR PI1012301A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- methods
- same
- cyclodextrin derivative
- compositions
- Prior art date
Links
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 title 1
- 229960001924 melphalan Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18256009P | 2009-05-29 | 2009-05-29 | |
| PCT/US2010/036736 WO2010138920A1 (en) | 2009-05-29 | 2010-05-28 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012301A2 true BRPI1012301A2 (pt) | 2015-09-22 |
Family
ID=43223125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012301A BRPI1012301A2 (pt) | 2009-05-29 | 2010-05-28 | composições de melfalano injetáveis compreendendo um derivado de ciclodextrina e métodos de preparar e usar o mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20100311838A1 (pt) |
| EP (1) | EP2434886B1 (pt) |
| JP (2) | JP5914328B2 (pt) |
| KR (1) | KR101522918B1 (pt) |
| CN (2) | CN102458114A (pt) |
| AU (1) | AU2010253905B2 (pt) |
| BR (1) | BRPI1012301A2 (pt) |
| CA (1) | CA2763365C (pt) |
| EA (1) | EA022890B1 (pt) |
| ES (1) | ES2767880T3 (pt) |
| IL (1) | IL216405A (pt) |
| MX (2) | MX388477B (pt) |
| NZ (1) | NZ596515A (pt) |
| PL (1) | PL2434886T3 (pt) |
| WO (1) | WO2010138920A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US11020363B2 (en) * | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
| MX388477B (es) * | 2009-05-29 | 2025-03-12 | Cydex Pharmaceuticals Inc | Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas. |
| EP4083075A1 (en) | 2012-02-15 | 2022-11-02 | CyDex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| WO2013130666A1 (en) | 2012-02-28 | 2013-09-06 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| MX360192B (es) | 2012-10-22 | 2018-10-24 | Cydex Pharmaceuticals Inc | Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas. |
| ITMI20130896A1 (it) * | 2013-05-31 | 2014-12-01 | Farmabios Spa | Processo di purificazione di melphalan |
| JP6914188B2 (ja) | 2014-08-22 | 2021-08-04 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| US10537520B2 (en) * | 2015-06-30 | 2020-01-21 | Leiutis Pharmaceuticals Pvt. Ltd. | Stable liquid formulations of melphalan |
| US20180237377A1 (en) * | 2015-07-29 | 2018-08-23 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the Synthesis of Melphalan and the Hydrochloride Salt |
| WO2017085696A1 (en) * | 2015-11-20 | 2017-05-26 | Leiutis Pharmaceuticals Pvt Ltd | Parenteral formulations of melphalan |
| MX2019013053A (es) * | 2017-05-03 | 2020-02-07 | Cydex Pharmaceuticals Inc | Composicion que contiene ciclodextrina y busulfan. |
| WO2020091797A1 (en) * | 2018-11-01 | 2020-05-07 | Children's Hospital Medical Center | Reduced intensity conditioning with melphalan |
| US20220205982A1 (en) * | 2019-05-16 | 2022-06-30 | Children's Hospital Medical Center | Methods for determining personalized full dose of melphalan in reduced intensity regimen prior to hematopoietic cell transplantation |
| US10682326B1 (en) | 2019-06-03 | 2020-06-16 | Shilpa Medicare Limited | Stable melphalan liquid injectable formulations |
| EP4055005A4 (en) * | 2019-11-04 | 2023-11-29 | Intas Pharmaceuticals Ltd. | Liquid melphalan composition |
| US11857677B2 (en) * | 2019-12-19 | 2024-01-02 | Rk Pharma Inc. | Ready to use injectable formulations of melphalan and processes for preparation thereof |
| JP1661983S (pt) | 2019-12-19 | 2020-06-22 | ||
| WO2022147743A1 (en) * | 2021-01-08 | 2022-07-14 | Quadriga Biosciences, Inc. | Pharmaceutical compositions of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) * | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| US3032585A (en) * | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5760015A (en) | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
| MY106598A (en) | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
| WO1991004026A1 (en) * | 1989-09-14 | 1991-04-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0518930A4 (en) | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
| EP0485614B1 (en) | 1990-05-21 | 1997-08-13 | Toppan Printing Co., Ltd. | Cyclodextrin derivative |
| US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
| ATE196426T1 (de) | 1991-06-21 | 2000-10-15 | Takeda Chemical Industries Ltd | Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate |
| US5446030A (en) | 1991-09-19 | 1995-08-29 | Weisz; Paul B. | Prevention of hemolysis |
| WO1993017711A1 (en) | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| FR2692168B1 (fr) | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| CA2159890A1 (en) | 1993-04-07 | 1994-10-13 | Joseph S. Sentendrey | Method of forming laminated fire resistant flexible sheet material and resulting product |
| US5407672A (en) | 1993-04-08 | 1995-04-18 | Cornell Research Foundation, Inc. | Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase |
| DK0695169T3 (da) | 1993-04-22 | 2003-03-17 | Skyepharma Inc | Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse |
| US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| US5925669A (en) | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
| IT1269578B (it) | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| US5935941A (en) | 1997-10-24 | 1999-08-10 | Pitha; Josef | Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| IT1291362B1 (it) | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
| JP4439596B2 (ja) | 1997-06-13 | 2010-03-24 | サイデクス ファーマシューティカルズ、 インク． | 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法 |
| EP0889056B1 (en) | 1997-07-01 | 2006-04-12 | Pfizer Products Inc. | Process for making a cyclodextrin |
| WO1999002177A1 (de) | 1997-07-07 | 1999-01-21 | Peptichemio Ag | Pharmazeutische zusammensetzung enthaltend peptichemio |
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| FR2775435B1 (fr) | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| AU6527300A (en) | 1999-08-11 | 2001-03-05 | Josef Pitha | Potentiation of inclusion complex formation of cyclodextrin derivatives |
| CN1303107C (zh) | 1999-11-12 | 2007-03-07 | 皮萨及皮萨有限公司 | β－环糊精的部分甲醚化产物和相关化合物的结晶混合物 |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| US20030119761A1 (en) | 2000-04-12 | 2003-06-26 | Christian Samuel T. | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use |
| US20060189547A1 (en) | 2000-04-12 | 2006-08-24 | Christian Samuel T | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use |
| AU2001253620A1 (en) * | 2000-04-14 | 2001-10-30 | Nuvelo, Inc. | Materials and methods relating to lipid metabolism |
| EP1294403A2 (en) | 2000-06-14 | 2003-03-26 | Corixa Corporation | Tripeptide prodrug compounds |
| US6699505B2 (en) | 2000-10-17 | 2004-03-02 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by compexing with cyclodextrins |
| CN1455863A (zh) | 2000-10-27 | 2003-11-12 | 宝洁公司 | 改进的消费产品套盒及其应用方法 |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US7229645B2 (en) | 2001-06-08 | 2007-06-12 | Powderject Research Limited | Spray freeze-dried compositions |
| US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| EP1443969A2 (en) | 2001-10-18 | 2004-08-11 | Decode Genetics EHF | Non-inclusion cyclodextrin complexes |
| KR20030041577A (ko) | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
| US6780324B2 (en) | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| CN1232539C (zh) | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| JP4175846B2 (ja) | 2002-08-08 | 2008-11-05 | 独立行政法人科学技術振興機構 | Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制 |
| RU2359698C2 (ru) | 2002-09-13 | 2009-06-27 | Сайдекс, Инк. | Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина |
| RU2005114007A (ru) | 2002-10-09 | 2005-10-10 | Инсерт Терапьютикс, Инк. (Us) | Материалы на основе циклодекстринов, их композиции и применение |
| US6933289B2 (en) * | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| WO2005117911A2 (en) | 2004-05-06 | 2005-12-15 | Cydex, Inc. | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| JP2005345549A (ja) * | 2004-05-31 | 2005-12-15 | Sumitomo Electric Ind Ltd | 光モジュール |
| EP1761283A2 (en) | 2004-06-07 | 2007-03-14 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
| WO2006052921A2 (en) | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
| DE602005026556D1 (de) | 2004-12-07 | 2011-04-07 | Proteolix Inc | Zusammensetzung zur proteasomhemmung |
| MX336033B (es) | 2005-08-03 | 2016-01-07 | Immunogen Inc | Formulaciones de inmunoconjugado. |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| CN100503647C (zh) | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20080085882A1 (en) * | 2006-08-18 | 2008-04-10 | University Of North Texas Health Science Center At Fort Worth | Compositions and Methods for Potentiation of Cancer Agents |
| BRPI0717460A2 (pt) | 2006-10-20 | 2013-12-24 | Icos Corp | Composições de inibidores de chk1 |
| WO2009018069A2 (en) | 2007-07-30 | 2009-02-05 | Cydex Pharmaceuticals, Inc | Mixtures of cyclodextrin derivatives |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| AR066943A1 (es) * | 2008-06-10 | 2009-09-23 | Eriochem Sa | Una composicion farmaceutica de melfalano |
| US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
| MX388477B (es) * | 2009-05-29 | 2025-03-12 | Cydex Pharmaceuticals Inc | Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas. |
| AR077384A1 (es) * | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
-
2010
- 2010-05-28 MX MX2018008597A patent/MX388477B/es unknown
- 2010-05-28 BR BRPI1012301A patent/BRPI1012301A2/pt not_active Application Discontinuation
- 2010-05-28 ES ES10781347T patent/ES2767880T3/es active Active
- 2010-05-28 PL PL10781347T patent/PL2434886T3/pl unknown
- 2010-05-28 JP JP2012513334A patent/JP5914328B2/ja active Active
- 2010-05-28 CN CN2010800334958A patent/CN102458114A/zh active Pending
- 2010-05-28 CN CN201610365810.6A patent/CN106389307A/zh active Pending
- 2010-05-28 EP EP10781347.9A patent/EP2434886B1/en active Active
- 2010-05-28 MX MX2011012640A patent/MX357677B/es active IP Right Grant
- 2010-05-28 AU AU2010253905A patent/AU2010253905B2/en active Active
- 2010-05-28 KR KR1020117030997A patent/KR101522918B1/ko active Active
- 2010-05-28 CA CA2763365A patent/CA2763365C/en active Active
- 2010-05-28 WO PCT/US2010/036736 patent/WO2010138920A1/en not_active Ceased
- 2010-05-28 EA EA201190297A patent/EA022890B1/ru not_active IP Right Cessation
- 2010-05-28 US US12/790,724 patent/US20100311838A1/en not_active Abandoned
- 2010-05-28 NZ NZ596515A patent/NZ596515A/en unknown
-
2011
- 2011-11-17 IL IL216405A patent/IL216405A/en active IP Right Grant
-
2013
- 2013-12-16 US US14/108,169 patent/US10940128B2/en active Active
-
2016
- 2016-01-29 JP JP2016015379A patent/JP6060289B2/ja active Active
-
2021
- 2021-03-08 US US17/194,980 patent/US20210379000A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/244,141 patent/US20240156766A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL216405A (en) | 2017-12-31 |
| US20140221488A1 (en) | 2014-08-07 |
| CA2763365A1 (en) | 2010-12-02 |
| IL216405A0 (en) | 2012-02-29 |
| US20210379000A1 (en) | 2021-12-09 |
| EP2434886A4 (en) | 2014-01-15 |
| JP2012528795A (ja) | 2012-11-15 |
| PL2434886T3 (pl) | 2020-05-18 |
| JP2016117748A (ja) | 2016-06-30 |
| AU2010253905A1 (en) | 2011-12-08 |
| EA201190297A1 (ru) | 2013-01-30 |
| EP2434886B1 (en) | 2019-10-16 |
| US20240156766A1 (en) | 2024-05-16 |
| WO2010138920A1 (en) | 2010-12-02 |
| CN102458114A (zh) | 2012-05-16 |
| JP6060289B2 (ja) | 2017-01-11 |
| JP5914328B2 (ja) | 2016-05-11 |
| EP2434886A1 (en) | 2012-04-04 |
| KR101522918B1 (ko) | 2015-05-27 |
| AU2010253905B2 (en) | 2014-10-02 |
| NZ596515A (en) | 2014-03-28 |
| MX2018008597A (es) | 2019-07-29 |
| US20100311838A1 (en) | 2010-12-09 |
| MX388477B (es) | 2025-03-12 |
| EA022890B1 (ru) | 2016-03-31 |
| MX2011012640A (es) | 2012-01-12 |
| CA2763365C (en) | 2016-09-13 |
| MX357677B (es) | 2018-07-19 |
| US10940128B2 (en) | 2021-03-09 |
| CN106389307A (zh) | 2017-02-15 |
| ES2767880T3 (es) | 2020-06-18 |
| KR20120041701A (ko) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012301A2 (pt) | composições de melfalano injetáveis compreendendo um derivado de ciclodextrina e métodos de preparar e usar o mesmo | |
| BRPI0919155A2 (pt) | composição aquosa injetável | |
| IT1400768B1 (it) | Componente micromeccanico | |
| BRPI1012285A2 (pt) | composições de resinas que compreendem derivados de lignina | |
| EP2262892A4 (en) | EXPRESSION OF HETEROLOGOUS SEQUENCES | |
| EP2356462A4 (en) | ANTI-CXCR1 COMPOSITIONS AND METHOD | |
| EP2351920A4 (en) | TURBOCHARGER | |
| IT1397181B1 (it) | Componente micromeccanico | |
| EP2261482A4 (en) | TURBOCHARGER | |
| DK3078664T3 (da) | Antiparasitiske dihydroazol-sammensætninger | |
| EP2488022A4 (en) | Compositions | |
| EP2306018A4 (en) | PIEZOELECTRIC MICRO FAN | |
| EP2312158A4 (en) | PIEZOELECTRIC MICRO FAN | |
| DK2634231T3 (da) | Sammensætninger | |
| BR112012004108A2 (pt) | composições de poliidroxialcanoato endurecidas | |
| FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
| BRPI0923191A2 (pt) | metodos relacionados com glicanos modificados | |
| UY33161A (es) | Composiciones plaguicidas | |
| EP2398631A4 (en) | INJECTION MOLDING APPARATUS | |
| BRPI1010690A2 (pt) | composições | |
| EP2277678A4 (en) | Exterior component | |
| EP2405936A4 (en) | INJECTABLE BIOMATERIALS | |
| BRPI1005919A2 (pt) | composição imunogênica | |
| EP2318306A4 (en) | NANOCOMPOSITES | |
| EP2515938A4 (en) | IMMUNOGENIC COMPOSITIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/04 Ipc: A61K 31/198 (2006.01), A61K 31/70 (2006.01), A61K |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |